Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

CMS continues to restrict coverage of amyloid-targeting antibodies for Alzheimer’s

By Brian Buntz | February 23, 2023

CMS

[Image courtesy of CMS]

CMS has denied the Alzheimer’s Association’s request asking for broader reimbursement support for FDA-approved monoclonal antibodies targeting amyloid.

In April 2022, CMS decided to limit coverage of such antibodies for Alzheimer’s to clinical trial volunteers. At that time, aducanumab from Biogen (Nasdaq: BIIB) and Eisai (TYO:4523) was the only FDA-approved antibody for the neurodegenerative condition.

CMS noted in an announcement that its latest decision rests on the current lack of evidence that amyloid-targeting antibodies are effective against Alzheimer’s.

Amyloid-targeting antibodies intend to treat Alzheimer’s by targeting and removing amyloid beta, a protein that accumulates in Alzheimer’s patients’ brains. The protein deposits eventually result in plaques that interfere with normal brain function.

Alzheimer’s organizations upset with the CMS

Alzheimer’s Association president and CEO Joanne Pike lambasted the decision, saying it is not CMS’s role to “stand between a patient and a doctor when deciding what FDA-approved treatments are appropriate.”

“Their role is not to single out people living with Alzheimer’s and decide that their lives, their independence and their memories are not necessary,” she continued.

Global Alzheimer’s Platform Foundation President John Dwyer criticized the decision, categorizing CMS’s decision as “outrageous.” He said the agency has “discriminated against 1.2 million Americans with Alzheimer’s who can benefit from a class of disease-modifying therapies that can help extend their life, memory and independence.”

Another advocacy organization, Voices of Alzheimer’s, also criticized the decision. “We believe that CMS is standing by the decision to deny medically necessary care because they want to control costs,” noted Jim Taylor, the organization’s president and CEO.

Efficacy and money questions

Assessing the efficacy of monoclonal antibodies targeting amyloid remains a thorny subject. In 2021, several FDA advisory committee members resigned after the agency conditionally approved aducanumab. One described the approval as the “worst” in recent U.S. history.

Biogen initially priced aducanumab at roughly $56,000 per year. An internal document from the company suggested that the company hoped aducanumab’s debut would be “one of the top pharmaceutical launches of all time,” according to The New Yorker. Biogen later cut the price in half.

Eisai said it would charge $26,500 per year for lecanemab.

Lecanemab could prove to be more effective than aducanumab. In an 18-month study in patients with early Alzheimer’s, it slowed the rate of cognitive decline by 27%.

The agency notes that it seeks to help improve care for Alzheimer’s patients. It states that it will expeditiously review new evidence that could convince it to reconsider the national coverage determinations for amyloid-targeting antibodies for Alzheimer’s.

To date, aducanumab and another antibody, lecanemab, have received accelerated FDA approval. CMS notes that it would provide broader coverage to the antibody class if an Alzheimer’s disease treatment wins traditional FDA approval.

Eisai anticipates that FDA will grant traditional approval to lecanemab, whose tradename is Leqembi, this summer.


Filed Under: Neurological Disease
Tagged With: amyloid, Biogen, Eisai, lecanemab
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

FDA expands Vizamyl label to include quantification and therapy monitoring, creating new competitive edge
AbbVie announces head-to-head results challenging migraine treatment status quo
Human study tracks brain’s glymphatic flow in real time, opening Alzheimer’s drug avenues
An 8-year-old patient with gangliosidosis demonstrates improved mobility, walking unassisted on a soccer field after treatment with N-acetyl-L-leucine. (Still from video footage; parental consent obtained for use).
Modified amino acid approved for Niemann–Pick shows promise in early Parkinson’s research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE